Share Price and Basic Stock Data
Last Updated: December 20, 2025, 3:20 pm
| PEG Ratio | 4.84 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ajanta Pharma Ltd has demonstrated commendable growth in its operations, with sales rising from ₹3,341 Cr in FY 2022 to ₹3,743 Cr in FY 2023, marking a notable increase of around 12%. The latest figures for FY 2024 indicate a further upward trajectory, with sales reported at ₹4,209 Cr. This consistent growth trajectory is encouraging, particularly in a highly competitive pharmaceutical landscape. The company’s quarterly sales performance also reflects this momentum, with the most recent quarter (September 2023) recording sales of ₹1,028 Cr, up from ₹1,021 Cr in June 2023. This steady increase in sales suggests strong demand for its products, which include a broad portfolio of formulations and specialty products. However, it is essential to note that while the revenue growth appears robust, the overall profitability margins have shown fluctuations, raising questions about the sustainability of this growth amid rising costs.
Profitability and Efficiency Metrics
Ajanta Pharma’s profitability metrics have shown some resilience, with the net profit for FY 2023 reported at ₹588 Cr, which rose to ₹920 Cr in FY 2025. The net profit margin has also improved, standing at 19.8% for FY 2025, compared to 15.71% in FY 2023. The operating profit margin (OPM) has remained relatively stable, reported at 27% for FY 2025, which is commendable given the pressures from increasing operational costs. However, the company’s interest coverage ratio (ICR) of 65.32x suggests that it is well-equipped to handle its interest obligations, indicating operational efficiency. On the flip side, the cash conversion cycle (CCC) has slightly stretched to 246 days, reflecting potential inefficiencies in inventory management or collections that could impact cash flows if not addressed. Overall, while Ajanta Pharma’s profitability metrics look strong, the management must focus on optimizing operational efficiency to sustain these margins.
Balance Sheet Strength and Financial Ratios
The balance sheet of Ajanta Pharma showcases a healthy financial position, with total reserves reaching ₹4,290 Cr against borrowings of only ₹246 Cr. This low leverage indicates a conservative approach to financing, which is generally favorable for long-term stability. The return on equity (ROE) stands at a robust 24.9%, and return on capital employed (ROCE) is at 32.4%, reflecting effective capital utilization. However, the price-to-book value ratio of 8.66x indicates that the stock is trading at a premium compared to its book value, which might raise concerns among value investors. Furthermore, the current ratio of 2.85x suggests that Ajanta Pharma is well-positioned to meet its short-term obligations. While the balance sheet appears strong, investors should monitor the company’s ability to sustain these ratios in light of fluctuating market conditions and regulatory challenges in the pharmaceutical sector.
Shareholding Pattern and Investor Confidence
Ajanta Pharma’s shareholding pattern reveals a stable and concentrated ownership structure, with promoters holding 66.25% of the shares. This significant promoter stake is a positive signal, as it often indicates strong alignment between management and shareholders. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 8.53% and 17.90%, respectively, suggesting moderate confidence from institutional players. However, the slight decline in FII holdings from 10.07% in December 2022 to 8.53% in September 2025 may indicate some caution among foreign investors, possibly due to global economic uncertainties. The number of shareholders has increased to 67,785, reflecting growing retail interest in the stock, which could provide a buffer against volatility. Overall, the shareholding structure appears favorable, but the decline in FII interest is a factor worth monitoring for potential shifts in investor sentiment.
Outlook, Risks, and Final Insight
Looking ahead, Ajanta Pharma faces both opportunities and challenges. The consistent revenue growth suggests potential for further expansion, particularly in emerging markets and therapeutic segments. However, risks such as regulatory scrutiny, fluctuating raw material costs, and competition from generic drugs could impact profitability. Additionally, while the company has a solid financial foundation, the high price-to-book value ratio may deter some value-conscious investors. The increasing cash conversion cycle also indicates potential inefficiencies that could affect liquidity. Investors should weigh these risks against the company’s strong fundamentals and growth prospects. A balanced perspective will be crucial for navigating the evolving landscape of the pharmaceutical industry and making informed investment decisions regarding Ajanta Pharma.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 151 Cr. | 120 | 235/84.3 | 33.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,413 Cr. | 405 | 479/192 | 91.4 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.7 Cr. | 48.2 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.3 Cr. | 33.0 | 33.0/17.0 | 115 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,162.24 Cr | 1,151.80 | 52.60 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 951 | 938 | 972 | 882 | 1,021 | 1,028 | 1,105 | 1,054 | 1,145 | 1,187 | 1,146 | 1,170 | 1,303 |
| Expenses | 729 | 742 | 802 | 732 | 750 | 738 | 791 | 776 | 815 | 875 | 825 | 873 | 951 |
| Operating Profit | 222 | 196 | 170 | 149 | 271 | 291 | 314 | 278 | 330 | 311 | 321 | 297 | 351 |
| OPM % | 23% | 21% | 17% | 17% | 27% | 28% | 28% | 26% | 29% | 26% | 28% | 25% | 27% |
| Other Income | 33 | 40 | 35 | 37 | 32 | 21 | 14 | 36 | 26 | 19 | 30 | 18 | 26 |
| Interest | 1 | 1 | 3 | 1 | 1 | 2 | 2 | 2 | 1 | 6 | 8 | 6 | 5 |
| Depreciation | 32 | 33 | 33 | 33 | 33 | 34 | 34 | 34 | 34 | 34 | 36 | 40 | 41 |
| Profit before tax | 222 | 203 | 168 | 152 | 269 | 276 | 291 | 278 | 322 | 290 | 307 | 269 | 331 |
| Tax % | 21% | 23% | 20% | 20% | 23% | 29% | 28% | 27% | 24% | 25% | 24% | 16% | 23% |
| Net Profit | 175 | 157 | 135 | 122 | 208 | 195 | 210 | 203 | 246 | 216 | 233 | 225 | 255 |
| EPS in Rs | 13.63 | 12.22 | 10.50 | 9.54 | 16.24 | 15.24 | 16.39 | 15.82 | 19.68 | 17.33 | 18.64 | 18.03 | 20.44 |
Last Updated: August 2, 2025, 12:40 am
Below is a detailed analysis of the quarterly data for Ajanta Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,303.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,170.00 Cr. (Mar 2025) to 1,303.00 Cr., marking an increase of 133.00 Cr..
- For Expenses, as of Jun 2025, the value is 951.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 873.00 Cr. (Mar 2025) to 951.00 Cr., marking an increase of 78.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 351.00 Cr.. The value appears strong and on an upward trend. It has increased from 297.00 Cr. (Mar 2025) to 351.00 Cr., marking an increase of 54.00 Cr..
- For OPM %, as of Jun 2025, the value is 27.00%. The value appears strong and on an upward trend. It has increased from 25.00% (Mar 2025) to 27.00%, marking an increase of 2.00%.
- For Other Income, as of Jun 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Mar 2025) to 26.00 Cr., marking an increase of 8.00 Cr..
- For Interest, as of Jun 2025, the value is 5.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.00 Cr. (Mar 2025) to 5.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 41.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 40.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 331.00 Cr.. The value appears strong and on an upward trend. It has increased from 269.00 Cr. (Mar 2025) to 331.00 Cr., marking an increase of 62.00 Cr..
- For Tax %, as of Jun 2025, the value is 23.00%. The value appears to be increasing, which may not be favorable. It has increased from 16.00% (Mar 2025) to 23.00%, marking an increase of 7.00%.
- For Net Profit, as of Jun 2025, the value is 255.00 Cr.. The value appears strong and on an upward trend. It has increased from 225.00 Cr. (Mar 2025) to 255.00 Cr., marking an increase of 30.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 20.44. The value appears strong and on an upward trend. It has increased from 18.03 (Mar 2025) to 20.44, marking an increase of 2.41.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:41 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,208 | 1,474 | 1,749 | 1,983 | 2,126 | 2,055 | 2,588 | 2,890 | 3,341 | 3,743 | 4,209 | 4,648 | 4,973 |
| Expenses | 840 | 968 | 1,155 | 1,292 | 1,467 | 1,489 | 1,904 | 1,889 | 2,408 | 2,934 | 3,037 | 3,379 | 3,676 |
| Operating Profit | 369 | 505 | 594 | 691 | 658 | 567 | 683 | 1,001 | 933 | 808 | 1,172 | 1,269 | 1,297 |
| OPM % | 31% | 34% | 34% | 35% | 31% | 28% | 26% | 35% | 28% | 22% | 28% | 27% | 26% |
| Other Income | 14 | 8 | 14 | 20 | 24 | 21 | 88 | 24 | 112 | 74 | 85 | 85 | 134 |
| Interest | 9 | 6 | 5 | 1 | 0 | 1 | 12 | 8 | 10 | 6 | 7 | 21 | 23 |
| Depreciation | 44 | 52 | 44 | 61 | 60 | 72 | 96 | 116 | 125 | 131 | 135 | 144 | 160 |
| Profit before tax | 330 | 456 | 559 | 648 | 623 | 514 | 664 | 900 | 909 | 745 | 1,114 | 1,189 | 1,249 |
| Tax % | 29% | 32% | 26% | 22% | 25% | 25% | 30% | 27% | 22% | 21% | 27% | 23% | |
| Net Profit | 234 | 310 | 416 | 507 | 469 | 387 | 468 | 654 | 713 | 588 | 816 | 920 | 974 |
| EPS in Rs | 17.75 | 23.47 | 31.49 | 38.40 | 35.50 | 29.56 | 35.73 | 50.38 | 55.63 | 45.89 | 63.70 | 73.68 | 77.94 |
| Dividend Payout % | 15% | 17% | 17% | 23% | 0% | 20% | 24% | 13% | 11% | 15% | 79% | 38% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 32.48% | 34.19% | 21.88% | -7.50% | -17.48% | 20.93% | 39.74% | 9.02% | -17.53% | 38.78% | 12.75% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1.71% | -12.32% | -29.37% | -9.99% | 38.41% | 18.81% | -30.72% | -26.55% | 56.31% | -26.03% |
Ajanta Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 12% |
| 3 Years: | 12% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 9% |
| TTM: | 9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 21% |
| 3 Years: | 25% |
| 1 Year: | -19% |
| Return on Equity | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 22% |
| 3 Years: | 22% |
| Last Year: | 25% |
Last Updated: September 4, 2025, 10:30 pm
Balance Sheet
Last Updated: December 4, 2025, 12:55 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 17 | 17 | 25 | 25 | 25 | 25 |
| Reserves | 576 | 823 | 1,173 | 1,550 | 2,024 | 2,228 | 2,581 | 2,978 | 3,247 | 3,363 | 3,542 | 3,765 | 4,290 |
| Borrowings | 130 | 72 | 81 | 1 | 2 | 36 | 75 | 31 | 25 | 36 | 35 | 47 | 246 |
| Other Liabilities | 226 | 233 | 207 | 254 | 383 | 383 | 619 | 702 | 711 | 1,159 | 927 | 1,067 | 1,112 |
| Total Liabilities | 949 | 1,146 | 1,479 | 1,823 | 2,426 | 2,664 | 3,293 | 3,729 | 4,000 | 4,582 | 4,530 | 4,904 | 5,672 |
| Fixed Assets | 279 | 288 | 451 | 589 | 1,053 | 1,178 | 1,472 | 1,541 | 1,512 | 1,496 | 1,479 | 1,762 | 1,873 |
| CWIP | 94 | 170 | 240 | 339 | 61 | 262 | 132 | 108 | 153 | 209 | 256 | 176 | 146 |
| Investments | 63 | 60 | 86 | 182 | 190 | 78 | 79 | 176 | 147 | 535 | 349 | 464 | 874 |
| Other Assets | 513 | 629 | 703 | 713 | 1,122 | 1,147 | 1,610 | 1,904 | 2,188 | 2,341 | 2,446 | 2,502 | 2,779 |
| Total Assets | 949 | 1,146 | 1,479 | 1,823 | 2,426 | 2,664 | 3,293 | 3,729 | 4,000 | 4,582 | 4,530 | 4,904 | 5,672 |
Below is a detailed analysis of the balance sheet data for Ajanta Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00 Cr..
- For Reserves, as of Sep 2025, the value is 4,290.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,765.00 Cr. (Mar 2025) to 4,290.00 Cr., marking an increase of 525.00 Cr..
- For Borrowings, as of Sep 2025, the value is 246.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 47.00 Cr. (Mar 2025) to 246.00 Cr., marking an increase of 199.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,112.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,067.00 Cr. (Mar 2025) to 1,112.00 Cr., marking an increase of 45.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 5,672.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,904.00 Cr. (Mar 2025) to 5,672.00 Cr., marking an increase of 768.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,873.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,762.00 Cr. (Mar 2025) to 1,873.00 Cr., marking an increase of 111.00 Cr..
- For CWIP, as of Sep 2025, the value is 146.00 Cr.. The value appears to be declining and may need further review. It has decreased from 176.00 Cr. (Mar 2025) to 146.00 Cr., marking a decrease of 30.00 Cr..
- For Investments, as of Sep 2025, the value is 874.00 Cr.. The value appears strong and on an upward trend. It has increased from 464.00 Cr. (Mar 2025) to 874.00 Cr., marking an increase of 410.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,779.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,502.00 Cr. (Mar 2025) to 2,779.00 Cr., marking an increase of 277.00 Cr..
- For Total Assets, as of Sep 2025, the value is 5,672.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,904.00 Cr. (Mar 2025) to 5,672.00 Cr., marking an increase of 768.00 Cr..
Notably, the Reserves (4,290.00 Cr.) exceed the Borrowings (246.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 239.00 | 433.00 | 513.00 | 690.00 | 656.00 | 531.00 | 608.00 | -30.00 | 908.00 | 772.00 | -34.00 | -46.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 64 | 78 | 59 | 79 | 82 | 109 | 93 | 111 | 103 | 108 | 93 |
| Inventory Days | 164 | 159 | 180 | 186 | 315 | 415 | 276 | 434 | 347 | 283 | 283 | 308 |
| Days Payable | 132 | 109 | 128 | 157 | 224 | 214 | 202 | 212 | 143 | 147 | 159 | 155 |
| Cash Conversion Cycle | 94 | 114 | 130 | 88 | 170 | 282 | 184 | 315 | 315 | 240 | 233 | 246 |
| Working Capital Days | 39 | 56 | 78 | 65 | 103 | 113 | 108 | 126 | 140 | 83 | 119 | 97 |
| ROCE % | 55% | 57% | 52% | 46% | 34% | 24% | 27% | 32% | 29% | 23% | 32% | 32% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 1,674,471 | 0.63 | 428.8 | 1,977,744 | 2025-12-08 07:42:13 | -15.33% |
| UTI Flexi Cap Fund | 1,425,000 | 1.43 | 364.91 | 1,415,187 | 2025-12-14 16:27:00 | 0.69% |
| Kotak Small Cap Fund | 1,219,302 | 1.79 | 312.24 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 959,323 | 2.9 | 245.66 | 968,214 | 2025-12-08 04:19:42 | -0.92% |
| Canara Robeco Large and Mid Cap Fund | 928,520 | 0.91 | 237.78 | N/A | N/A | N/A |
| HDFC Large and Mid Cap Fund | 897,224 | 0.8 | 229.76 | N/A | N/A | N/A |
| UTI Mid Cap Fund | 840,000 | 1.79 | 215.11 | N/A | N/A | N/A |
| Nippon India Multi Cap Fund | 807,460 | 0.41 | 206.77 | 628,966 | 2025-12-08 02:19:27 | 28.38% |
| Canara Robeco Small Cap Fund | 579,013 | 1.14 | 148.27 | 546,991 | 2025-12-07 16:44:29 | 5.85% |
| PGIM India Midcap Fund | 454,661 | 1.01 | 116.43 | 424,692 | 2025-12-14 03:33:18 | 7.06% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 73.56 | 64.82 | 45.89 | 82.45 | 75.09 |
| Diluted EPS (Rs.) | 73.53 | 64.77 | 45.89 | 82.45 | 75.09 |
| Cash EPS (Rs.) | 84.92 | 75.31 | 56.89 | 97.61 | 88.55 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 302.38 | 282.34 | 268.14 | 380.24 | 344.52 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 302.38 | 282.34 | 268.14 | 380.24 | 344.52 |
| Revenue From Operations / Share (Rs.) | 370.81 | 333.10 | 296.21 | 389.17 | 332.34 |
| PBDIT / Share (Rs.) | 108.02 | 99.45 | 69.80 | 121.72 | 117.83 |
| PBIT / Share (Rs.) | 96.52 | 88.73 | 59.45 | 107.13 | 104.48 |
| PBT / Share (Rs.) | 94.87 | 88.16 | 58.98 | 105.94 | 103.53 |
| Net Profit / Share (Rs.) | 73.43 | 64.60 | 46.54 | 83.01 | 75.20 |
| NP After MI And SOA / Share (Rs.) | 73.43 | 64.60 | 46.54 | 83.01 | 75.20 |
| PBDIT Margin (%) | 29.13 | 29.85 | 23.56 | 31.27 | 35.45 |
| PBIT Margin (%) | 26.02 | 26.63 | 20.06 | 27.52 | 31.43 |
| PBT Margin (%) | 25.58 | 26.46 | 19.91 | 27.22 | 31.15 |
| Net Profit Margin (%) | 19.80 | 19.39 | 15.71 | 21.33 | 22.62 |
| NP After MI And SOA Margin (%) | 19.80 | 19.39 | 15.71 | 21.33 | 22.62 |
| Return on Networth / Equity (%) | 24.28 | 22.87 | 17.35 | 21.83 | 21.82 |
| Return on Capital Employeed (%) | 30.10 | 29.95 | 21.21 | 26.98 | 29.02 |
| Return On Assets (%) | 18.35 | 17.59 | 12.56 | 17.57 | 17.30 |
| Asset Turnover Ratio (%) | 0.96 | 0.90 | 0.81 | 0.83 | 0.79 |
| Current Ratio (X) | 2.85 | 3.05 | 2.49 | 3.50 | 3.13 |
| Quick Ratio (X) | 1.95 | 2.12 | 1.77 | 2.28 | 1.94 |
| Inventory Turnover Ratio (X) | 5.37 | 1.14 | 1.19 | 1.10 | 1.25 |
| Dividend Payout Ratio (NP) (%) | 38.00 | 78.68 | 15.25 | 11.53 | 12.67 |
| Dividend Payout Ratio (CP) (%) | 32.85 | 67.48 | 12.47 | 9.81 | 10.76 |
| Earning Retention Ratio (%) | 62.00 | 21.32 | 84.75 | 88.47 | 87.33 |
| Cash Earning Retention Ratio (%) | 67.15 | 32.52 | 87.53 | 90.19 | 89.24 |
| Interest Coverage Ratio (X) | 65.32 | 174.28 | 151.01 | 102.45 | 123.89 |
| Interest Coverage Ratio (Post Tax) (X) | 45.40 | 114.20 | 101.68 | 70.87 | 80.07 |
| Enterprise Value (Cr.) | 32649.25 | 28149.11 | 14945.61 | 15321.67 | 15384.30 |
| EV / Net Operating Revenue (X) | 7.02 | 6.69 | 3.99 | 4.59 | 5.32 |
| EV / EBITDA (X) | 24.11 | 22.40 | 16.95 | 14.66 | 15.02 |
| MarketCap / Net Operating Revenue (X) | 7.06 | 6.72 | 4.08 | 4.65 | 5.40 |
| Retention Ratios (%) | 61.99 | 21.31 | 84.74 | 88.46 | 87.32 |
| Price / BV (X) | 8.66 | 7.93 | 4.51 | 4.76 | 5.21 |
| Price / Net Operating Revenue (X) | 7.06 | 6.72 | 4.08 | 4.65 | 5.40 |
| EarningsYield | 0.02 | 0.02 | 0.03 | 0.04 | 0.04 |
After reviewing the key financial ratios for Ajanta Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 73.56. This value is within the healthy range. It has increased from 64.82 (Mar 24) to 73.56, marking an increase of 8.74.
- For Diluted EPS (Rs.), as of Mar 25, the value is 73.53. This value is within the healthy range. It has increased from 64.77 (Mar 24) to 73.53, marking an increase of 8.76.
- For Cash EPS (Rs.), as of Mar 25, the value is 84.92. This value is within the healthy range. It has increased from 75.31 (Mar 24) to 84.92, marking an increase of 9.61.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 302.38. It has increased from 282.34 (Mar 24) to 302.38, marking an increase of 20.04.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 302.38. It has increased from 282.34 (Mar 24) to 302.38, marking an increase of 20.04.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 370.81. It has increased from 333.10 (Mar 24) to 370.81, marking an increase of 37.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 108.02. This value is within the healthy range. It has increased from 99.45 (Mar 24) to 108.02, marking an increase of 8.57.
- For PBIT / Share (Rs.), as of Mar 25, the value is 96.52. This value is within the healthy range. It has increased from 88.73 (Mar 24) to 96.52, marking an increase of 7.79.
- For PBT / Share (Rs.), as of Mar 25, the value is 94.87. This value is within the healthy range. It has increased from 88.16 (Mar 24) to 94.87, marking an increase of 6.71.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 73.43. This value is within the healthy range. It has increased from 64.60 (Mar 24) to 73.43, marking an increase of 8.83.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 73.43. This value is within the healthy range. It has increased from 64.60 (Mar 24) to 73.43, marking an increase of 8.83.
- For PBDIT Margin (%), as of Mar 25, the value is 29.13. This value is within the healthy range. It has decreased from 29.85 (Mar 24) to 29.13, marking a decrease of 0.72.
- For PBIT Margin (%), as of Mar 25, the value is 26.02. This value exceeds the healthy maximum of 20. It has decreased from 26.63 (Mar 24) to 26.02, marking a decrease of 0.61.
- For PBT Margin (%), as of Mar 25, the value is 25.58. This value is within the healthy range. It has decreased from 26.46 (Mar 24) to 25.58, marking a decrease of 0.88.
- For Net Profit Margin (%), as of Mar 25, the value is 19.80. This value exceeds the healthy maximum of 10. It has increased from 19.39 (Mar 24) to 19.80, marking an increase of 0.41.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 19.80. This value is within the healthy range. It has increased from 19.39 (Mar 24) to 19.80, marking an increase of 0.41.
- For Return on Networth / Equity (%), as of Mar 25, the value is 24.28. This value is within the healthy range. It has increased from 22.87 (Mar 24) to 24.28, marking an increase of 1.41.
- For Return on Capital Employeed (%), as of Mar 25, the value is 30.10. This value is within the healthy range. It has increased from 29.95 (Mar 24) to 30.10, marking an increase of 0.15.
- For Return On Assets (%), as of Mar 25, the value is 18.35. This value is within the healthy range. It has increased from 17.59 (Mar 24) to 18.35, marking an increase of 0.76.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.96. It has increased from 0.90 (Mar 24) to 0.96, marking an increase of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 2.85. This value is within the healthy range. It has decreased from 3.05 (Mar 24) to 2.85, marking a decrease of 0.20.
- For Quick Ratio (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has decreased from 2.12 (Mar 24) to 1.95, marking a decrease of 0.17.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.37. This value is within the healthy range. It has increased from 1.14 (Mar 24) to 5.37, marking an increase of 4.23.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 38.00. This value is within the healthy range. It has decreased from 78.68 (Mar 24) to 38.00, marking a decrease of 40.68.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 32.85. This value is within the healthy range. It has decreased from 67.48 (Mar 24) to 32.85, marking a decrease of 34.63.
- For Earning Retention Ratio (%), as of Mar 25, the value is 62.00. This value is within the healthy range. It has increased from 21.32 (Mar 24) to 62.00, marking an increase of 40.68.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 67.15. This value is within the healthy range. It has increased from 32.52 (Mar 24) to 67.15, marking an increase of 34.63.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 65.32. This value is within the healthy range. It has decreased from 174.28 (Mar 24) to 65.32, marking a decrease of 108.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 45.40. This value is within the healthy range. It has decreased from 114.20 (Mar 24) to 45.40, marking a decrease of 68.80.
- For Enterprise Value (Cr.), as of Mar 25, the value is 32,649.25. It has increased from 28,149.11 (Mar 24) to 32,649.25, marking an increase of 4,500.14.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.02. This value exceeds the healthy maximum of 3. It has increased from 6.69 (Mar 24) to 7.02, marking an increase of 0.33.
- For EV / EBITDA (X), as of Mar 25, the value is 24.11. This value exceeds the healthy maximum of 15. It has increased from 22.40 (Mar 24) to 24.11, marking an increase of 1.71.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.06. This value exceeds the healthy maximum of 3. It has increased from 6.72 (Mar 24) to 7.06, marking an increase of 0.34.
- For Retention Ratios (%), as of Mar 25, the value is 61.99. This value is within the healthy range. It has increased from 21.31 (Mar 24) to 61.99, marking an increase of 40.68.
- For Price / BV (X), as of Mar 25, the value is 8.66. This value exceeds the healthy maximum of 3. It has increased from 7.93 (Mar 24) to 8.66, marking an increase of 0.73.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.06. This value exceeds the healthy maximum of 3. It has increased from 6.72 (Mar 24) to 7.06, marking an increase of 0.34.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ajanta Pharma Ltd:
- Net Profit Margin: 19.8%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 30.1% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 24.28% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 45.4
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.95
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 33.8 (Industry average Stock P/E: 52.6)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 19.8%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Ajanta House, Charkop, Kandivli (West), Mumbai Maharashtra 400067 | info@ajantapharma.com http://www.ajantapharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mannalal B Agrawal | Chairman |
| Mr. Madhusudan B Agrawal | Vice Chairman |
| Mr. Yogesh M Agrawal | Managing Director |
| Mr. Rajesh M Agrawal | Joint Managing Director |
| Mr. David Rasquinha | Independent Director |
| Ms. Medha Joshi | Independent Director |
| Mr. Rajesh Dalal | Independent Director |
| Ms. Simi Thapar | Independent Director |
FAQ
What is the intrinsic value of Ajanta Pharma Ltd?
Ajanta Pharma Ltd's intrinsic value (as of 21 December 2025) is 2347.49 which is 10.84% lower the current market price of 2,633.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 32,891 Cr. market cap, FY2025-2026 high/low of 3,116/2,022, reserves of ₹4,290 Cr, and liabilities of 5,672 Cr.
What is the Market Cap of Ajanta Pharma Ltd?
The Market Cap of Ajanta Pharma Ltd is 32,891 Cr..
What is the current Stock Price of Ajanta Pharma Ltd as on 21 December 2025?
The current stock price of Ajanta Pharma Ltd as on 21 December 2025 is 2,633.
What is the High / Low of Ajanta Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ajanta Pharma Ltd stocks is 3,116/2,022.
What is the Stock P/E of Ajanta Pharma Ltd?
The Stock P/E of Ajanta Pharma Ltd is 33.8.
What is the Book Value of Ajanta Pharma Ltd?
The Book Value of Ajanta Pharma Ltd is 345.
What is the Dividend Yield of Ajanta Pharma Ltd?
The Dividend Yield of Ajanta Pharma Ltd is 1.06 %.
What is the ROCE of Ajanta Pharma Ltd?
The ROCE of Ajanta Pharma Ltd is 32.4 %.
What is the ROE of Ajanta Pharma Ltd?
The ROE of Ajanta Pharma Ltd is 24.9 %.
What is the Face Value of Ajanta Pharma Ltd?
The Face Value of Ajanta Pharma Ltd is 2.00.